{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:39:04Z","timestamp":1759941544893,"version":"3.44.0"},"reference-count":32,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001515","name":"Cure Kids","doi-asserted-by":"publisher","award":["3588"],"award-info":[{"award-number":["3588"]}],"id":[{"id":"10.13039\/501100001515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["20\/302"],"award-info":[{"award-number":["20\/302"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2022,12,19]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine if very low dose (VLD, 0.5% phenylephrine, 0.1% cyclopentolate) mydriatic microdrop (approximately 7 \u03bcL) administration (up to three doses) is non-inferior to low dose (LD, 1% phenylephrine, 0.2% cyclopentolate) mydriatic microdrop administration for ophthalmologist-determined successful retinopathy of prematurity eye examination (ROPEE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Multicentre, prospective, randomised controlled, non-inferiority clinical trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Four neonatal intensive care units in Aotearoa, New Zealand from October 2019 to September 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>Infants with a birth weight less than 1250 g or gestational age less than 30+6 weeks and who required a ROPEE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>The intervention: microdrop (approximately 7 \u03bcL) of VLD (0.5% phenylephrine and 0.1% cyclopentolate) to both eyes, or the comparison: microdrop of LD (1% phenylephrine and 0.2% cyclopentolate) to both eyes. Up to three doses could be administered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>The primary outcome measure was an ophthalmologist-determined successful ROPEE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred and fifty preterm infants (LD mean GA=27.4\u00b11.8 weeks, mean birth weight=1011\u00b1290 g, VLD mean GA=27.5\u00b11.9 weeks, mean birth weight=1049\u00b1281 g,) were randomised. Non-inferiority for successful ROPEE was demonstrated for the VLD group compared with the LD group (VLD successful ROPEE=100%, LD successful ROPEE=100%, 95% CI no continuity correction \u22120.05 to 0.05) and for M\u0101ori (95% CI no continuity correction \u22120.02 to 0.19).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>VLD microdrops enable safe and effective screening for ROPEE in both M\u0101ori and non-M\u0101ori preterm infants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>ACTRN12619000795190.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/archdischild-2022-324929","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T13:20:23Z","timestamp":1672665623000},"page":"380-386","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Low dose or very low dose phenylephrine and cyclopentolate microdrops for retinopathy of prematurity eye examinations (The Little Eye Drop Study): a randomised controlled non-inferiority trial"],"prefix":"10.1136","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9068-4391","authenticated-orcid":false,"given":"Lisa Jean","family":"Kremer","sequence":"first","affiliation":[{"name":"He Rau Kawakawa (School of Pharmacy), University of Otago Division of Health Sciences, Dunedin, New Zealand"},{"name":"Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Medlicott","sequence":"additional","affiliation":[{"name":"He Rau Kawakawa (School of Pharmacy), University of Otago Division of Health Sciences, Dunedin, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jane","family":"Sime","sequence":"additional","affiliation":[{"name":"Ophthalmology, Te Whatu Ora (Health New Zealand), Southern, Dunedin, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Broadbent","sequence":"additional","affiliation":[{"name":"Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago Dunedin School of Medicine, Dunedin, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Edmonds","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, K\u014dhatu Centre for Hauora M\u0101ori, University of Otago, Dunedin, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Judith","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, University of Otago Wellington, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola C","family":"Austin","sequence":"additional","affiliation":[{"name":"Neonatal Paediatrics, University of Otago Christchurch, Christchurch, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0874-6654","authenticated-orcid":false,"given":"Jane M","family":"Alsweiler","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, The University of Auckland School of Medicine, Auckland, New Zealand"},{"name":"Newborn Services, Auckland Hospital, Te Whatu Ora Health New Zealand, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M","family":"Reith","sequence":"additional","affiliation":[{"name":"Deans Department, University of Otago Dunedin School of Medicine, Dunedin, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"key":"2025090513255075000_108.4.380.1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/jcn.JCN_102_18","article-title":"Management of retinopathy of prematurity in a neonatal unit: current approach","volume":"8","author":"Parappil","year":"2019","journal-title":"J Clin Neonatol"},{"key":"2025090513255075000_108.4.380.2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74 Suppl 1","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"2025090513255075000_108.4.380.3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1055\/s-0041-1726316","article-title":"A survey of neonatal nurses on mydriatic regimens used in neonatal retinopathy of prematurity eye examinations","volume":"39","author":"Kremer","year":"2022","journal-title":"Am J Perinatol"},{"key":"2025090513255075000_108.4.380.4","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(82)90081-9"},{"key":"2025090513255075000_108.4.380.5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/1874364101711010305","article-title":"A Single Drop in the Eye - Effects on the Whole Body?","volume":"11","author":"Vaajanen","year":"2017","journal-title":"Open Ophthalmol J"},{"key":"2025090513255075000_108.4.380.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2019-000448","article-title":"Systematic review of mydriatics used for screening of retinopathy in premature infants","volume":"3","author":"Kremer","year":"2019","journal-title":"BMJ Paediatr Open"},{"key":"2025090513255075000_108.4.380.7","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-318733"},{"key":"2025090513255075000_108.4.380.8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41372-021-01229-w","article-title":"Efficacy and safety of mydriatic microdrops for retinopathy of prematurity screening: an external pilot crossover randomized controlled trial","volume":"42","author":"Seliniotaki","year":"2022","journal-title":"J Perinatol"},{"key":"2025090513255075000_108.4.380.9","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-197801000-00001"},{"key":"2025090513255075000_108.4.380.10","unstructured":"Health Mo . Ethnicty code tables. Wellington, New Zealand: Health Mo, 2010."},{"key":"2025090513255075000_108.4.380.11","unstructured":"European Medicines Agency for Medicinal Products for Human Use (CHMP) . Guideline on the choice of the non-inferiority margin. London: EMA, 2005. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-choice-non-inferiority-margin_en.pdf"},{"key":"2025090513255075000_108.4.380.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256878","article-title":"Systemic adverse events after screening of retinopathy of prematurity with mydriatic","volume":"16","author":"Obata","year":"2021","journal-title":"PLoS One"},{"key":"2025090513255075000_108.4.380.13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaapos.2012.02.017","article-title":"A randomized controlled trial to determine the lowest effective dose for adequate mydriasis in premature infants","volume":"16","author":"Vicente","year":"2012","journal-title":"J Aapos"},{"key":"2025090513255075000_108.4.380.14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3928\/01913913-20050501-05","article-title":"Comparison of mydriatic regimens used in screening for retinopathy of prematurity in preterm infants with dark irides","volume":"42","author":"Chew","year":"2005","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2025090513255075000_108.4.380.15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3928\/0191-3913-20000101-05","article-title":"Combination cyclopentolate and phenylephrine for mydriasis in premature infants with heavily pigmented irides","volume":"37","author":"Khoo","year":"2000","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2025090513255075000_108.4.380.16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/OPX.0b013e3181cc8da3","article-title":"Comparison of two drug combinations for dilating dark irides","volume":"87","author":"Anderson","year":"2010","journal-title":"Optom Vis Sci"},{"key":"2025090513255075000_108.4.380.17","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.107842"},{"key":"2025090513255075000_108.4.380.18","first-page":"47","article-title":"Necrotising enterocolitis following the use of mydriatics: a case report of two triplets","volume":"16","author":"Siu","year":"2011","journal-title":"Hong Kong Journal of Paediatrics"},{"key":"2025090513255075000_108.4.380.19","first-page":"S147","article-title":"Fatal necrotising enterocolitis due to mydriatic eye drops","volume":"24 Suppl 2","author":"Ozgun","year":"2014","journal-title":"J Coll Physicians Surg Pak"},{"key":"2025090513255075000_108.4.380.20","unstructured":"Centre for Adverse Reactions Monitoring (CARM) . Phenylephrine 2.5% and cyclopentolate 0.5% adverse effects. Case Report 2014:111811."},{"key":"2025090513255075000_108.4.380.21","unstructured":"Centre for Adverse Reactions Monitoring (CARM) . Phenylephrine 1% and cyclopentolate 0.5% adverse effects. Case Report 2002:54093."},{"key":"2025090513255075000_108.4.380.22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5152\/balkanmedj.2012.064","article-title":"Suspected central anticholinergic syndrome related to cycloplegic eye drop in a premature baby","volume":"29","author":"Bedirli","year":"2012","journal-title":"Balkan Med J"},{"key":"2025090513255075000_108.4.380.23","first-page":"419","article-title":"Myoclonic seizure due to cyclopentolate eye drop in a preterm infant","volume":"54","author":"B\u00fcy\u00fckcam","year":"2012","journal-title":"Turk J Pediatr"},{"key":"2025090513255075000_108.4.380.24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1542\/peds.68.2.231","article-title":"Increased blood pressure following pupillary dilation with 2.5% phenylephrine hydrochloride in preterm infants","volume":"68","author":"Lees","year":"1981","journal-title":"Pediatrics"},{"key":"2025090513255075000_108.4.380.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0890-6"},{"key":"2025090513255075000_108.4.380.26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4067\/S0370-41062017000200014","article-title":"[Periorbital pallor post application of mydriatic in infants with hydrocephalus associated to systemic effects]","volume":"88","author":"Alvarado Socarras","year":"2017","journal-title":"Rev Chil Pediatr"},{"key":"2025090513255075000_108.4.380.27","first-page":"203","article-title":"Renal failure caused by eyedrops containing phenylephrine in a case of retinopathy of prematurity","volume":"50","author":"Shinomiya","year":"2003","journal-title":"J Med Invest"},{"key":"2025090513255075000_108.4.380.28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3928\/23258160-20210727-10","article-title":"Retinopathy of prematurity screening examination and changes in vital signs","volume":"52","author":"Lahoti","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2025090513255075000_108.4.380.29","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3109\/02713683.2015.1136419","article-title":"Systemic absorption of cyclopentolate and adverse events after retinopathy of prematurity exams","volume":"41","author":"Mitchell","year":"2016","journal-title":"Curr Eye Res"},{"key":"2025090513255075000_108.4.380.30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijgo.13855","article-title":"He Tamariki Kokoti tau: tackling preterm incidence and outcomes of preterm births by ethnicity in Aotearoa New Zealand 2010\u20132014","volume":"155","author":"Edmonds","year":"2021","journal-title":"Intl J Gynecology & Obste"},{"key":"2025090513255075000_108.4.380.31","unstructured":"Smith LT . Decolonizing methodologies : research and indigenous peoples. London: Zed Books, 1999."},{"key":"2025090513255075000_108.4.380.32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.puhe.2019.03.026","article-title":"Indigenous data and health: critical approaches to 'race'\/ethnicity and Indigenous data governance","volume":"172","author":"Cormack","year":"2019","journal-title":"Public Health"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2022-324929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T20:26:04Z","timestamp":1757103964000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/archdischild-2022-324929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,2]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,6,19]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/archdischild-2022-324929"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2022-324929","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"type":"print","value":"1359-2998"},{"type":"electronic","value":"1468-2052"}],"subject":[],"published":{"date-parts":[[2023,1,2]]}}}